PMA device
Herceptest
Agilent Technologies Singapore (International) Pte , Ltd. · System, Test, Her-2/Neu, Ihc (MVC, Class III) · First FDA decision Dec 30, 2005, newest Apr 18, 2013Breast cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
0
Naming "Herceptest"
MAUDE reports
8
Brand "Herceptest", since 2015
PubMed studies
372
Mentioning "Herceptest"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Herceptest
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- HERCEPTESTPMA supplement
P980018-S017 · Decided Apr 18, 2013 · 168 days after receipt · Normal 180 Day Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Herceptest", any status and sponsor, newest update first.
No registered device study names "Herceptest".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Herceptest", and for the whole product code for context.
This brand
8 reports: 4 malfunction, 1 injury, 0 death
Whole product code MVC
12 reports: 4 malfunction, 5 injury, 0 death
Newest reports for this brand
- HERCEPTEST FOR AUTO LINK PLATFORMS, BR+GAMalfunction
AGILENT TECHNOLOGIES SINGAPORE (INTL.) PTE LTD.
3003423869-2024-00013 · Received Feb 26, 2024 · Event dated Feb 2, 2024
Device type: Immunohistochemistry Reagents And Kits (NJT)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0113-06 · Started Sep 29, 2005 · Posted by FDA Nov 1, 2005
Reason given: Formulation error in the Visualization Reagent (vial 3) component contained in Hercep Test kits. The error was in the concentration of Polyethylene Glycol contained in the formulation.
Cause as FDA categorized it: Other · Device type: System, Test, Her-2/Neu, Ihc (MVC)
Published research
The most relevant PubMed records for "Herceptest"[tiab]. The summary above synthesizes these.
- Oncology drug-companion diagnostic combinations.
Jørgensen JT · Cancer Treat Res Commun · 2021
- Twenty-five years with companion diagnostics.
Jørgensen JT · Chin Clin Oncol · 2023
- Potential impact of HercepTestࡊ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis.
Marszaek A, Kubicka A, Jagieo I, et al. · Pol J Pathol · 2023
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
Hofmann M, Stoss O, Shi D, et al. · Histopathology · 2008Comparative Study, Consensus Statement
- Herceptest: HER2 expression and gene amplification in non-small cell lung cancer.
Cox G, Vyberg M, Melgaard B, et al. · Int J Cancer · 2001
- HER2 testing: evolution and update for a companion diagnostic assay.
Robbins CJ, Bates KM, Rimm DL · Nat Rev Clin Oncol · 2025Review
- [HER-2 diagnostics].
Bánkfalvi A · Magy Onkol · 2002English Abstract, Review
- Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
Navarro Sanchez JM, Finkelman BS, Tyburski H, et al. · Hum Pathol · 2024Comparative Study
- Comparison of HercepTestࡊ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J, Friedrich M, Nagelmeier I, et al. · Virchows Arch · 2022
- Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
Robbins CJ, Fernandez AI, Han G, et al. · Mod Pathol · 2023Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Molecular tools for companion diagnostics.
Zieba A, Grannas K, Söderberg O, et al. · N Biotechnol · 2012Research Support, Non-U.S. Gov't, Review
- Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma.
Miladinovik M, Vučkovik L, Klisic A · Open Med (Wars) · 2021
Other devices of this type
Also filed under product code MVC.
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2026
- Bond Oracle HER2 Ihc SystemLeica Biosystems · PMA 2014
- Hercep TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2012
- PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2025
- Hercap TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Pathway Her 2 (Clone CB11)Ventana Medical Systems, Inc. · PMA 2002
- Pathway ANTI-HCR-2/NCU (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.